ASMB · CIK 0001426800
ASSEMBLY BIOSCIENCES, INC.
What ASSEMBLY BIOSCIENCES, INC. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
ASSEMBLY BIOSCIENCES, INC. - Profile
- Industry
- Pharmaceutical PreparationsSIC 2834
- Listed on
- Nasdaq
- Employees
- 73stated 2025
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from ASSEMBLY BIOSCIENCES, INC.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from Assembly Biosciences, Inc. Form 10-K for fiscal year 2025, Assembly Biosciences, Inc. Form 10-Q for the quarter ended 30 June 2026 and Gilead Sciences, Inc. Form 13F-HR information table for the quarter ended 30 June 2026, not taken from any single article.
Share price
ASMB
Description
Assembly Biosciences, Inc. is a biotechnology company in South San Francisco, California that develops small molecule therapeutics for serious viral diseases. Its clinical-stage pipeline centres on two long-acting helicase-primase inhibitors for recurrent genital herpes (ABI-5366 and ABI-1179), an orally bioavailable hepatitis delta virus entry inhibitor (ABI-6250) and a next-generation hepatitis B capsid assembly modulator (ABI-4334), alongside ABI-7272, an oral broad-spectrum polymerase inhibitor for transplant-associated herpesviruses that is in regulatory filing enabling studies. Gilead Sciences has been the central partner since October 2023, when a 12 year option, license and collaboration agreement and the accompanying equity agreements brought in $100.0 million. Gilead exercised its option on the herpes program in December 2025, owned about 25.1% of the common stock at 30 June 2026, and reported 4,977,089 shares (CUSIP 045396207, the security created by the 1-for-12 reverse split of February 2024) in its 30 June 2026 Form 13F. There is no approved product. Collaboration revenue from Gilead was $72.3 million in 2025 against $84.4 million of operating expenses, for a net loss of $6.1 million, and the accumulated deficit reached $845.0 million by 30 June 2026. Cash, cash equivalents and marketable securities were $320.4 million at 30 June 2026.
Who owns ASSEMBLY BIOSCIENCES, INC..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 72 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
72 managers reported a position, together holding 13.8m shares, or 86.5% of the company. The 40 largest are listed. Percentages are of the 15.9m shares outstanding at 1 May 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 26 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 045396207, held by ameriprise, bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, franklin-resources, geode, gilead, goldman-sachs, invesco, jpmorgan, metlife, morgan-stanley, northern-trust, state-street, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.